A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of CRTE7A2-01 TCR-T Cell for HPV16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
Latest Information Update: 30 Jun 2022
At a glance
- Drugs CRTE7A2-01 T cell receptor T-cell therapy-Beijing Kerui Biotechnology (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Interleukin-2 (Primary)
- Indications Anal cancer; Cervical cancer; Head and neck cancer
- Focus Adverse reactions
- Sponsors Beijing Kerui Biotechnology
- 22 Jun 2022 Status changed from not yet recruiting to recruiting.
- 19 Nov 2021 New trial record